RFRaphaella Ferreira

Raphaella Ferreira

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Raphaella Ferreira has a total of 58 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Alpha-1 Antitrypsin Deficiency in Patients With Cirrhosis in a US National Cohort

    by Binu V. John, Dustin Bastaich, Andres Samos, Austen Hentschel, Sunny Sandhu, Raphaella D. Ferreira, Tamar Taddei, Brian Garnet, David E. Kaplan, Michael Campos, et al.

    INTRODUCTION: Alpha-1 antitrypsin deficiency (AATD) is a genetic condition that increases susceptibility to chronic lung and liver diseases. There are limited data on testing rates in patients with cirrhosis. Guidelines recommend AATD testing in cryptogenic liver disease but not in patients with an established etiology. We aimed to quantify AATD testing patterns in a national cohort of patients with cirrhosis to inform guidelines. METHODS: In this retrospective cohort study of veterans with a new diagnosis of cirrhosis between January 1, 2008 and January 31, 2020, with follow-up until February 23, 2023, we identified predictors of testing, and of severe AATD (alpha-1 antitrypsin [AAT] < 57 mg/dL or PiSZ/PiZZ phenotype/genotype). RESULTS: Of the 126,210 patients with cirrhosis, 42,403 (33.6%) were tested, including 38,189 (30.3%) for AAT levels only, 1,103 (0.8%) for genotype/phenotype only, and 3,011 (2.4%) for both. Factors associated with higher AATD testing included specialist evaluation and White race, whereas patients with chronic obstructive pulmonary disease, hepatitis B/C, hepatocellular carcinoma, and hepatic decompensation were less likely to be tested. Only half of the patients with AAT levels of <57 mg/dL underwent genotype/phenotype testing. Most patients (94.7%) with severe AATD-associated liver disease also had an alternate etiology of liver disease, including metabolic dysfunction associated with steatotic liver disease (53.6%) or viral hepatitis (16.1%), and would be missed if testing only patients with cryptogenic liver disease. DISCUSSION: AATD testing rates in veterans with cirrhosis are low, and patients at high-risk are less likely to be tested. Guidelines are needed to emphasize universal AATD testing in patients with cirrhosis regardless of the presence of other risk factors.


  • Identifying Metabolic Dysfunction-Associated Steatotic Liver Disease Using Natural Language Processing in a US National Cohort

    by Binu V. John, Dustin Bastaich, Catherine Mezzacappa, Raphaella D. Ferreira, Austen Hentschel, Andres Samos, Nadim Mahmud, Tamar H. Taddei, David Kaplan, Marina Serper, et al.

    INTRODUCTION: Although metabolic dysfunction-associated steatotic liver disease (MASLD) and MASLD with increased alcohol intake (MetALD) are identified as clinical entities; tools to identify patients from electronic health records (EHRs) to perform large outcome studies are lacking. METHODS: In this retrospective study of participants from the Veterans Analysis of Liver Disease cohort assembled from 1/1/2013 to 12/31/2022, a rule-based natural language processing (NLP) algorithm searched EHRs for imaging evidence of hepatic steatosis. This was combined with identification of cardiometabolic risk factors and harmful alcohol use. Algorithm-derived diagnoses of MASLD, MetALD, alcohol-associated steatotic liver disease (ALD), and no steatotic liver disease (SLD) were validated using a blinded review of randomly selected charts. RESULTS: Among 817,657 eligible veterans, SLD was present in over half (n = 438,209, 53.5%), including MASLD in 299,259 (36.5%), 99,163 with MetALD (12.1%), and 38,552 (4.7%) with ALD. The NLP algorithm had a high correlation with steatosis on chart review, with a κ of 0.86 (95% CI 0.82–0.90), sensitivity of 0.96, and specificity of 0.90. Classification of MASLD, MetALD, ALD, and no SLD by the algorithm also showed high correlation with chart review, with a κ of 0.87 (95% CI 0.82–0.91). This algorithm identified 299,259 (36.5%) of the study cohort with MASLD, compared with 23,218 patients (2.8%) identified using I nternational Classification of D iseases-9/10 codes. DISCUSSION: An algorithm combining rule-based NLP with cardiometabolic risk factors and alcohol use from EHRs accurately identifies and classifies SLD and can be applied in large epidemiologic studies of SLD in the Veterans Health Administration.


  • Open Access

    Cell-Free DNA as a Surveillance Tool for Hepatocellular Carcinoma Patients after Liver Transplant

    by Joao Manzi, Camilla O. Hoff, Raphaella Ferreira, Renata Glehn-Ponsirenas, Gennaro Selvaggi, Akin Tekin, Christopher B. O’brien, Lynn Feun, Rodrigo Vianna, Phillipe Abreu

    The liver is the world’s sixth most common primary tumor site, responsible for approximately 5% of all cancers and over 8% of cancer-related deaths. Hepatocellular carcinoma (HCC) is the predominant type of liver cancer, accounting for approximately 75% of all primary liver tumors. A major therapeutic tool for this disease is liver transplantation. Two of the most significant issues in treating HCC are tumor recurrence and graft rejection. Currently, the detection and monitoring of HCC recurrence and graft rejection mainly consist of imaging methods, tissue biopsies, and alpha-fetoprotein (AFP) follow-up. However, they have limited accuracy and precision. One of the many possible components of cfDNA is circulating tumor DNA (ctDNA), which is cfDNA derived from tumor cells. Another important component in transplantation is donor-derived cfDNA (dd-cfDNA), derived from donor tissue. All the components of cfDNA can be analyzed in blood samples as liquid biopsies. These can play a role in determining prognosis, tumor recurrence, and graft rejection, assisting in an overall manner in clinical decision-making in the treatment of HCC.


  • Open Access

    Targeted Therapies in Colorectal Cancer: Recent Advances in Biomarkers, Landmark Trials, and Future Perspectives

    by Joao Manzi, Camilla O. Hoff, Raphaella Ferreira, Agustin Pimentel, Jashodeep Datta, Alan S. Livingstone, Rodrigo Vianna, Phillipe Abreu

    In 2022, approximately 600,000 cancer deaths were expected; more than 50,000 of those deaths would be from colorectal cancer (CRC). The CRC mortality rate in the US has decreased in recent decades, with a 51% drop between 1976 and 2014. This drop is attributed, in part, to the tremendous therapeutic improvements, especially after the 2000s, in addition to increased social awareness regarding risk factors and diagnostic improvement. Five-fluorouracil, irinotecan, capecitabine, and later oxaliplatin were the mainstays of mCRC treatment from the 1960s to 2002. Since then, more than a dozen drugs have been approved for the disease, betting on a new chapter in medicine, precision oncology, which uses patient and tumor characteristics to guide the therapeutic choice. Thus, this review will summarize the current literature on targeted therapies, highlighting the molecular biomarkers involved and their pathways.


  • Third dose of COVID-19 mRNA vaccine appears to overcome vaccine hyporesponsiveness in patients with cirrhosis

    by Binu V. John, Raphaella D. Ferreira, Akash Doshi, David E. Kaplan, Tamar H. Taddei, Seth A. Spector, Elizabeth Paulus, Yangyang Deng, Dustin Bastaich, Bassam Dahman


  • Open Access

    314.10: Controlling the Cytokine Stom With Therapeutic Plasma Exchange: The MTI Experience With Solid Organ Transplant Recipients

    by Adela Mattiazzi, Shweta Anjan, Juliano Riella, Raphaella Ferreira, Luke Preczewski, Jacques Simkins, Yoichiro Natori, Giselle Guerra

  • Open Access

    Duodenopancreatectomy: influence of patient's intrinsic factors on results of pancreatic cancer surgical treatment

    by Álisson Carvalho de Freitas, Heloisa Porath, João Lucas Aleixes Sampaio Rocha, Regina Maria Goolkate, Raphaella Paula Ferreira, Phillipe Geraldo Teixeira de Abreu Reis

    Introduction: Pancreatic cancer is the fourth leading cause of cancer death in Western countries, with a more prevalent incidence in the elderly (1). It presents itself as a neoplasm with high lethality and low survival, surgical resection being the only treatment with curative potential. However, pancreatoduodenectomy (Kausch-Whipple technique) is one of the most difficult surgeries in the gastrointestinal system, due to the great difficulty in accessing the pancreas and its proximity to various delicate and vital structures, requiring advanced knowledge by the surgeon (6). Objective: Evaluate the profile of patients with pancreatic cancer and factors that contribute to the surgical outcome and survival after curative pancreatoduodenectomy. Method: A descriptive retrospective cross-sectional study was carried out through the analysis of records of pancreatoduodenectomy in the period May 2005 – July 2015 at Hospital Erasto Gaertner (HEG) in Curitiba/PR. Variables were analyzed using Student's t-test, non-parametric Mann-Whitney U test, and chi-squared test with Fisher's correction. Survival and disease-free survival rates were evaluated using the Kaplan-Maier method with the log-rank test and survival predictors identified with Cox regression. The SPSS 23.0 and STATA 15 programs were used, with p value being lower than 0.05 considered statistically significant. Results: 98 pancreatoduodenectomy were evaluated and 46 were in male patients and 30 were in patients aged <60 years. Ca 19-9 levels were elevated in 29% of patients before surgery and elevated in 5% after surgery. Regarding the location of the tumor, 77% were pancreatic, 14% were duodenal papilla and 8% were biliary tract. Regarding tumor histology, 81 were adenocarcinoma, 6 were cholangiocarcinoma and 5 were other diagnoses; 29% were well differentiated, 53% moderately and 17% poorly differentiated. About staging, 21% T1, 23% T2, 36% T3 and 18% T4 were found. Factors such as local tumor extension, location of the lesion and surgery time do not show a significant influence on the surgical outcome of these patients. The main postoperative complications were fistula and evisceration. The mean overall survival after surgery at 5 years was 12.24% and this was seen to be significantly higher in the <60 years group (p < 0.01). Discussion and Conclusion: It was seen that pancreatic tumors present in more advanced stages at diagnosis and are more prevalent in the elderly. These characteristics negatively impact 5-year overall survival rates, as this is higher in patients older than 60 years. Early diagnosis remains a challenge for successful treatment with curative potential, and remains a key point for the survival of these patients, as it allows for better staging and better surgical results.

  • Open Access

    Video-Assisted Jejunostomy Tube Placement With Two Portals: Surgical Technique in Ten Steps

    by Phillipe Abreu, Raphaella Ferreira, Victor Mineli, Danilo S. Bussyguin, Luiz B. Dantas, Luiz A. Szutan, Vinicius B. Preti, Rodrigo M. Vianna, Flavio D. S. Tomasich

    Objectives. Endoscopic gastrostomy occasionally presents limitations such as costs, availability of equipment and special materials, and difficult access to the gastric cavity in the setting of obstructive esophageal tumors. Open jejunostomies present high rates of postoperative complications and limited capacity for abdominal evaluation due to reduced incision size. Thus, to reduce procedure-related complications and overall costs and provide a thorough intraoperative evaluation of the peritoneal cavity, we present the following simplified technique. Methods. Video-assisted jejunostomy in ten steps. Results. The use of this Video-assisted laparoscopic technique proves to be a safe, viable alternative, with cost reduction, decreased use of disposable materials, shortened operative time, and accelerated recovery, in addition to increased technical ease and wide applicability across a variety of hospital settings.

  • Open Access

    Chronic pancreatitis with ductal stones in the pancreatic head treated by surgery: a case report

    by Alberto Meyer, Andreas Johann Molnar Koszka, Phillipe Abreu, Raphaella Ferreira, Marcelo Callado Fantauzzi, Vanderlei Segatelli, Andre Ibrahim David

    Pancreatic duct stones are direct sequelae of chronic pancreatitis (CP) and can occur in ∼50% of patients. Selection of the appropriate treatment method for pancreatic duct stones depends on location, size and number of stones. We present a patient with upper abdominal pain and weight loss for the previous 3 months. Diagnostic workup detected a chronic inflammation of the pancreas with stone in the main pancreatic duct and a nodular lesion in the head of the pancreas. Endoscopic retrograde cholangiopancreatography was performed without success. Given the rise in incidence and prevalence of CP, the potential complications and high mortality rate, it is imperative that physicians understand the risk factors, disease process and management of this disease. Pancreaticoduodenectomy in patients with CP is a feasible option for the treatment of focal cystic lesions to the head of the pancreas associated to pancreatic stone in selected cases.